These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22820140)

  • 1. Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma.
    Marečko I; Cvejić D; Tatić S; Dragutinović V; Paunović I; Savin S
    Cancer Biomark; 2011-2012; 11(1):49-58. PubMed ID: 22820140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas.
    Maeta H; Ohgi S; Terada T
    Virchows Arch; 2001 Feb; 438(2):121-8. PubMed ID: 11253113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of matrix metalloproteinase-2: a diagnostic marker but not prognostic marker of papillary thyroid carcinoma.
    Korem S; Kraiem Z; Shiloni E; Yehezkel O; Sadeh O; Resnick MB
    Isr Med Assoc J; 2002 Apr; 4(4):247-51. PubMed ID: 12001695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the membrane mucins MUC4 and MUC15, potential markers of malignancy and prognosis, in papillary thyroid carcinoma.
    Nam KH; Noh TW; Chung SH; Lee SH; Lee MK; Hong SW; Chung WY; Lee EJ; Park CS
    Thyroid; 2011 Jul; 21(7):745-50. PubMed ID: 21615302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical levels of matrix metalloproteinase-2 and CD44 variant 6 protein in the diagnosis and lateral cervical lymph node metastasis of papillary thyroid carcinoma.
    Wu G; Zhou Y; Li T; Guo J; Zhou Z
    J Int Med Res; 2013 Jun; 41(3):816-24. PubMed ID: 23685894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinase (MMP) expression by differentiated thyroid carcinoma of children and adolescents.
    Patel A; Straight AM; Mann H; Duffy E; Fenton C; Dinauer C; Tuttle RM; Francis GL
    J Endocrinol Invest; 2002 May; 25(5):403-8. PubMed ID: 12035934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in papillary thyroid cancer: an association with the clinical, morphological and ultrastructural characteristics of a tumor].
    Delektorskaia VV; Smirnova EA; Ponomareva MV; Pavlova TV; Pavlov IA
    Arkh Patol; 2010; 72(4):3-6. PubMed ID: 21086628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
    Buergy D; Weber T; Maurer GD; Mudduluru G; Medved F; Leupold JH; Brauckhoff M; Post S; Dralle H; Allgayer H
    Int J Cancer; 2009 Aug; 125(4):894-901. PubMed ID: 19480010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
    Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
    APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinase-9 and the Cu/Zn ratio as ancillary diagnostic tools in distinguishing between the classical and follicular variants of papillary thyroid carcinoma.
    Dragutinović VV; Tatić SB; Nikolić-Mandić S; Savin S; Cvejić D; Dunđerović D; Gajić M; Paunović I
    Biol Trace Elem Res; 2012 Oct; 149(1):29-33. PubMed ID: 22528774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of matrix metalloproteinases and their inhibitors in the development of cervical metastases in papillary thyroid cancer.
    Bumber B; Marjanovic Kavanagh M; Jakovcevic A; Sincic N; Prstacic R; Prgomet D
    Clin Otolaryngol; 2020 Jan; 45(1):55-62. PubMed ID: 31646745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human thyroid carcinoma cell lines and normal thyrocytes: expression and regulation of matrix metalloproteinase-1 and tissue matrix metalloproteinase inhibitor-1 messenger-RNA and protein.
    Aust G; Hofmann A; Laue S; Rost A; Köhler T; Scherbaum WA
    Thyroid; 1997 Oct; 7(5):713-24. PubMed ID: 9349574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid].
    Wang T; Jiang CX; Li Y; Liu X
    Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):824-8. PubMed ID: 20193458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the ROCK1/MMP-9 pathway is associated with the invasion and poor prognosis in papillary thyroid carcinoma.
    Luo D; Chen H; Li X; Lu P; Long M; Peng X; Lin S; Tan L; Zhu Y; Ouyang N; Li H
    Int J Oncol; 2017 Oct; 51(4):1209-1218. PubMed ID: 28848996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
    Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
    Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer.
    Zarkesh M; Zadeh-Vakili A; Akbarzadeh M; Fanaei SA; Hedayati M; Azizi F
    BMC Cancer; 2018 Dec; 18(1):1199. PubMed ID: 30509240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of matrix metalloproteinases and their specific inhibitors in normal and different human thyroid tumor cell lines.
    Baldini E; Toller M; Graziano FM; Russo FP; Pepe M; Biordi L; Marchioni E; Curcio F; Ulisse S; Ambesi-Impiombato FS; D'Armiento M
    Thyroid; 2004 Nov; 14(11):881-8. PubMed ID: 15671765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of MMP-13 is associated with invasion and metastasis of papillary thyroid carcinoma.
    Wang JR; Li XH; Gao XJ; An SC; Liu H; Liang J; Zhang K; Liu Z; Wang J; Chen Z; Sun W
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):427-35. PubMed ID: 23467939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of TGF-β1, SNAI1 and MMP-9 is associated with lymph node metastasis in papillary thyroid carcinoma.
    Wang N; Jiang R; Yang JY; Tang C; Yang L; Xu M; Jiang QF; Liu ZM
    J Mol Histol; 2014 Aug; 45(4):391-9. PubMed ID: 24276590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mRNA levels of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 and of their inhibitors TIMP-2 and TIMP-3 in normal thyrocytes and thyroid carcinoma cell lines.
    Hofmann A; Laue S; Rost AK; Scherbaum WA; Aust G
    Thyroid; 1998 Mar; 8(3):203-14. PubMed ID: 9545106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.